Cargando…

Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis

Target inhibitors are used for melanoma treatment, and their effectiveness depends on the tumor genotype. We developed a diagnostic biochip for the detection of 39 clinically relevant somatic mutations in the BRAF, NRAS, KIT, GNAQ, GNA11, MAP2K1 and MAP2K2 genes. We used multiplex locked nucleic aci...

Descripción completa

Detalles Bibliográficos
Autores principales: Emelyanova, Marina, Ghukasyan, Lilit, Abramov, Ivan, Ryabaya, Oxana, Stepanova, Evgenia, Kudryavtseva, Anna, Sadritdinova, Asiya, Dzhumakova, Cholpon, Belysheva, Tatiana, Surzhikov, Sergey, Lyubchenko, Lyudmila, Zasedatelev, Alexander, Nasedkina, Tatiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581030/
https://www.ncbi.nlm.nih.gov/pubmed/28881731
http://dx.doi.org/10.18632/oncotarget.17014
_version_ 1783260982477324288
author Emelyanova, Marina
Ghukasyan, Lilit
Abramov, Ivan
Ryabaya, Oxana
Stepanova, Evgenia
Kudryavtseva, Anna
Sadritdinova, Asiya
Dzhumakova, Cholpon
Belysheva, Tatiana
Surzhikov, Sergey
Lyubchenko, Lyudmila
Zasedatelev, Alexander
Nasedkina, Tatiana
author_facet Emelyanova, Marina
Ghukasyan, Lilit
Abramov, Ivan
Ryabaya, Oxana
Stepanova, Evgenia
Kudryavtseva, Anna
Sadritdinova, Asiya
Dzhumakova, Cholpon
Belysheva, Tatiana
Surzhikov, Sergey
Lyubchenko, Lyudmila
Zasedatelev, Alexander
Nasedkina, Tatiana
author_sort Emelyanova, Marina
collection PubMed
description Target inhibitors are used for melanoma treatment, and their effectiveness depends on the tumor genotype. We developed a diagnostic biochip for the detection of 39 clinically relevant somatic mutations in the BRAF, NRAS, KIT, GNAQ, GNA11, MAP2K1 and MAP2K2 genes. We used multiplex locked nucleic acid (LNA) PCR clamp for the preferable amplification of mutated over wild type DNA. The amplified fragments were labeled via the incorporation of fluorescently labeled dUTP during PCR and were hybridized with specific oligonucleotides immobilized on a biochip. This approach could detect 0.5% of mutated DNA in the sample analyzed. The method was validated on 253 clinical samples and six melanoma cell lines. Among 253 melanomas, 129 (51.0%) BRAF, 45 (17.8%) NRAS, 6 (2.4%) KIT, 4 (1.6%) GNAQ, 2 (0.8%) GNA11, 2 (0.8%) MAP2K1 and no MAP2K2 gene mutations were detected by the biochip assay. The results were compared with Sanger sequencing, next generation sequencing and ARMS/Scorpion real-time PCR. The specimens with discordant results were subjected to LNA PCR clamp followed by sequencing. The results of this analysis were predominantly identical to the results obtained by the biochip assay. Infrequently, we identified rare somatic mutations. In the present study we demonstrate that the biochip-based assay can effectively detect somatic mutations in approximately 70% of melanoma patients, who may require specific targeted therapy.
format Online
Article
Text
id pubmed-5581030
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55810302017-09-06 Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis Emelyanova, Marina Ghukasyan, Lilit Abramov, Ivan Ryabaya, Oxana Stepanova, Evgenia Kudryavtseva, Anna Sadritdinova, Asiya Dzhumakova, Cholpon Belysheva, Tatiana Surzhikov, Sergey Lyubchenko, Lyudmila Zasedatelev, Alexander Nasedkina, Tatiana Oncotarget Research Paper Target inhibitors are used for melanoma treatment, and their effectiveness depends on the tumor genotype. We developed a diagnostic biochip for the detection of 39 clinically relevant somatic mutations in the BRAF, NRAS, KIT, GNAQ, GNA11, MAP2K1 and MAP2K2 genes. We used multiplex locked nucleic acid (LNA) PCR clamp for the preferable amplification of mutated over wild type DNA. The amplified fragments were labeled via the incorporation of fluorescently labeled dUTP during PCR and were hybridized with specific oligonucleotides immobilized on a biochip. This approach could detect 0.5% of mutated DNA in the sample analyzed. The method was validated on 253 clinical samples and six melanoma cell lines. Among 253 melanomas, 129 (51.0%) BRAF, 45 (17.8%) NRAS, 6 (2.4%) KIT, 4 (1.6%) GNAQ, 2 (0.8%) GNA11, 2 (0.8%) MAP2K1 and no MAP2K2 gene mutations were detected by the biochip assay. The results were compared with Sanger sequencing, next generation sequencing and ARMS/Scorpion real-time PCR. The specimens with discordant results were subjected to LNA PCR clamp followed by sequencing. The results of this analysis were predominantly identical to the results obtained by the biochip assay. Infrequently, we identified rare somatic mutations. In the present study we demonstrate that the biochip-based assay can effectively detect somatic mutations in approximately 70% of melanoma patients, who may require specific targeted therapy. Impact Journals LLC 2017-04-10 /pmc/articles/PMC5581030/ /pubmed/28881731 http://dx.doi.org/10.18632/oncotarget.17014 Text en Copyright: © 2017 Emelyanova et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Emelyanova, Marina
Ghukasyan, Lilit
Abramov, Ivan
Ryabaya, Oxana
Stepanova, Evgenia
Kudryavtseva, Anna
Sadritdinova, Asiya
Dzhumakova, Cholpon
Belysheva, Tatiana
Surzhikov, Sergey
Lyubchenko, Lyudmila
Zasedatelev, Alexander
Nasedkina, Tatiana
Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis
title Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis
title_full Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis
title_fullStr Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis
title_full_unstemmed Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis
title_short Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis
title_sort detection of braf, nras, kit, gnaq, gna11 and map2k1/2 mutations in russian melanoma patients using lna pcr clamp and biochip analysis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581030/
https://www.ncbi.nlm.nih.gov/pubmed/28881731
http://dx.doi.org/10.18632/oncotarget.17014
work_keys_str_mv AT emelyanovamarina detectionofbrafnraskitgnaqgna11andmap2k12mutationsinrussianmelanomapatientsusinglnapcrclampandbiochipanalysis
AT ghukasyanlilit detectionofbrafnraskitgnaqgna11andmap2k12mutationsinrussianmelanomapatientsusinglnapcrclampandbiochipanalysis
AT abramovivan detectionofbrafnraskitgnaqgna11andmap2k12mutationsinrussianmelanomapatientsusinglnapcrclampandbiochipanalysis
AT ryabayaoxana detectionofbrafnraskitgnaqgna11andmap2k12mutationsinrussianmelanomapatientsusinglnapcrclampandbiochipanalysis
AT stepanovaevgenia detectionofbrafnraskitgnaqgna11andmap2k12mutationsinrussianmelanomapatientsusinglnapcrclampandbiochipanalysis
AT kudryavtsevaanna detectionofbrafnraskitgnaqgna11andmap2k12mutationsinrussianmelanomapatientsusinglnapcrclampandbiochipanalysis
AT sadritdinovaasiya detectionofbrafnraskitgnaqgna11andmap2k12mutationsinrussianmelanomapatientsusinglnapcrclampandbiochipanalysis
AT dzhumakovacholpon detectionofbrafnraskitgnaqgna11andmap2k12mutationsinrussianmelanomapatientsusinglnapcrclampandbiochipanalysis
AT belyshevatatiana detectionofbrafnraskitgnaqgna11andmap2k12mutationsinrussianmelanomapatientsusinglnapcrclampandbiochipanalysis
AT surzhikovsergey detectionofbrafnraskitgnaqgna11andmap2k12mutationsinrussianmelanomapatientsusinglnapcrclampandbiochipanalysis
AT lyubchenkolyudmila detectionofbrafnraskitgnaqgna11andmap2k12mutationsinrussianmelanomapatientsusinglnapcrclampandbiochipanalysis
AT zasedatelevalexander detectionofbrafnraskitgnaqgna11andmap2k12mutationsinrussianmelanomapatientsusinglnapcrclampandbiochipanalysis
AT nasedkinatatiana detectionofbrafnraskitgnaqgna11andmap2k12mutationsinrussianmelanomapatientsusinglnapcrclampandbiochipanalysis